UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000042998
Receipt number R000049038
Scientific Title A Comparative study between the diagnostic ability of EUS-FNA with 22-gauge franseen needle and that with 19-gauge franseen needle for autoimmune pancreatitis
Date of disclosure of the study information 2021/01/13
Last modified on 2023/01/15 18:48:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Comparative study between the diagnostic ability of EUS-FNA with 22-gauge franseen needle and that with 19-gauge franseen needle for autoimmune pancreatitis

Acronym

AIP-acquire 19G vs 22G study

Scientific Title

A Comparative study between the diagnostic ability of EUS-FNA with 22-gauge franseen needle and that with 19-gauge franseen needle for autoimmune pancreatitis

Scientific Title:Acronym

AIP-acquire 19G vs 22G study

Region

Japan


Condition

Condition

autoimmune pancreatitis

Classification by specialty

Hepato-biliary-pancreatic medicine

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare the diagnostic ability of EUS-FNA using 19-gauge franseen needle to that with 22-gauge franseen needle

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Pathological diagnostic rate of autoimmune pancreatitis

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Diagnosis

Type of intervention

Maneuver

Interventions/Control_1

A 19-gauge franseen needle is used in EUS-FNA prior to a 22-gauge franseen needle

Interventions/Control_2

A 22-gauge franseen needle is used in EUS-FNA prior to a 19-gauge franseen needle

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Need for pathological confirmation of type 1 autoimmune pancreatitis

Key exclusion criteria

Coagulopathy
Severe comorbidity(ASA class3 or more)
Low performance status(PS 4)
Severe hemodynamic disease or respiratory disease
Pregnancy or breast-feeding
Not suitable for the study

Target sample size

55


Research contact person

Name of lead principal investigator

1st name Toshifumi
Middle name
Last name Kin

Organization

Teine-Keijinkai Hospital

Division name

Center for Gastroenterology

Zip code

0068555

Address

1-40-1-12 Maeda, Teine-ku, Sapporo, Hokkaido, Japan

TEL

011-681-8111

Email

kin_toshifumi@yahoo.co.jp


Public contact

Name of contact person

1st name Toshifumi
Middle name
Last name Kin

Organization

Teine-Keijinkai Hospital

Division name

Center for Gastroenterology

Zip code

0068555

Address

1-40-1-12 Maeda, Teine-ku, Sapporo, Hokkaido, Japan

TEL

011-681-8111

Homepage URL


Email

kin_toshifumi@yahoo.co.jp


Sponsor or person

Institute

Teine-Keijinkai Hospital

Institute

Department

Personal name



Funding Source

Organization

None

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Teine-Keijinkai Hospital

Address

1-40-1-12 Maeda, Teine-ku, Sapporo, Hokkaido, Japan

Tel

011-681-8111

Email

kin_toshifumi@yahoo.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 01 Month 13 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

57

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2018 Year 07 Month 17 Day

Date of IRB

2018 Year 10 Month 31 Day

Anticipated trial start date

2019 Year 04 Month 01 Day

Last follow-up date

2023 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2021 Year 01 Month 13 Day

Last modified on

2023 Year 01 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049038


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name